Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.

Area of Science:

• Rheumatology
• Immunology
• Clinical Medicine

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease characterized by variable clinical manifestations and prognoses.
• Autoantibodies and the extent of skin involvement (cutaneous subset) are known to influence SSc progression and patient outcomes.

Purpose of the Study:

• To investigate the associations between specific autoantibodies, clinical presentation, and patient outcomes in a large cohort of SSc patients.
• To develop a novel classification scheme for SSc that integrates autoantibody profiles and cutaneous disease subsets.

Main Methods:

• A cohort of 1,325 SSc patients was analyzed for demographic and clinical characteristics, including autoantibody specificities and cutaneous subset.
• Survival analysis was employed to evaluate the impact of autoantibodies on organ involvement and mortality.

Main Results:

• Anticentromere antibody-positive limited cutaneous SSc (lcSSc) patients showed the best 20-year survival and lowest rates of pulmonary fibrosis and renal crisis.
• Anti-Scl-70 antibody-positive patients, particularly those with diffuse cutaneous SSc (dcSSc), exhibited high rates of pulmonary fibrosis and lower survival.
• Anti-RNA polymerase antibody positivity was associated with the highest incidence of scleroderma renal crisis, while anti-U3 RNP positivity correlated with increased pulmonary hypertension and cardiac SSc.

Conclusions:

• Autoantibodies, cutaneous subset, and disease duration are critical factors in assessing morbidity and mortality in SSc.
• The proposed novel classification scheme, incorporating autoantibodies and cutaneous subsets, has the potential to enhance disease monitoring and inform future clinical trial designs in SSc.